Personnel changes at Alchemia
Alchemia Limited announced the appointment of Thomas Liquard as Chief Executive Officer following the departure of Charles Walker. Mr Liquard, who joined Alchemia in December 2013 as Chief Operating Officer, brings significant commercial and managerial expertise to the company having most recently served as Senior Director, Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer, Inc. in New York.
“The company has been diligently preparing for its transformation into a broader commercial organization and with our pivotal Phase 3 trial data read-out on the horizon for HA-irinotecan, along with a developing oncology pipeline, we are delighted to make this CEO appointment,” stated Santo J. Costa, Alchemia’s Incoming Chairman. “Thomas’ impressive background and strategic mindset makes him extremely qualified to lead Alchemia through this next stage of corporate growth. On behalf of the Board, I wish to thank Charlie for his service over the last year in helping guide our transition to products beyond fondaparinux.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.